UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 11, 2010 BIO-BRIDGE SCIENCE, INC. (Exact name of registrant as specified in its charter)

SECURITIES AND EXCHANGE COMMISSION


DELAWARE	000-51497	20-1802936
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation or organization)		Identification No.)

Washington, D.C. 20549

1801 South Meyers Road, Suite 220, Oakbrook Terrace, IL	60181
(Address of Principal Executive Offices)	(Zip Code)

~~FORM 8~~630-K613-9687

~~CURRENT~~(Registrant’s ~~REPORT~~telephone number, including area code)

~~Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934~~N/A

~~Date of~~(Former ~~Report~~Name ~~(Date~~or ofFormer ~~earliest~~Address, ~~event~~if ~~reported): April~~Changed ~~12,~~Since ~~2010~~Last Report)

~~BIO~~Check the appropriate box below if the Form 8-~~BRIDGE~~K filing is intended to simultaneously ~~SCIENCE,~~satisfy ~~INC.~~the filing obligation of the registrant under any of the following provisions:

~~(Exact~~o Written communications pursuant to ~~name~~Rule of425 ~~registrant~~under asthe ~~specified~~Securities inAct ~~its~~(17 ~~charter~~CFR 230.425)

Delaware	000-51497	20-1802936
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

1211 West 22nd Street, Suite 615, Oak Brook, Illinois	60523
(Address of principal executive offices)	(Zip Code)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~Registrant’s~~o ~~telephone~~Pre-commencement ~~number,~~communications ~~including~~pursuant ~~area~~to ~~code: 630~~Rule 13e-~~928~~4(c) under the Exchange Act (17 CFR 240.13e-~~0869~~4(c))

~~Check~~Item ~~the appropriate~~5.02. ~~box~~Departure ~~below~~of ifDirectors ~~the~~or ~~Form~~Certain ~~8-K~~Officers; ~~filing~~Election isof ~~intended~~Directors; toAppointment ~~simultaneously satisfy the filing obligation~~ of ~~the~~Certain ~~registrant~~Officers; ~~under~~Compensatory ~~any~~Arrangements of ~~the~~Certain ~~following provisions (see General Instruction A~~Officers.~~2. below):~~

¨ (b) On ~~Written~~November ~~communications~~11, ~~pursuant~~2010, toChuen ~~Rule~~Huei ~~425~~(Kevin) ~~under~~Lee resigned, effective the ~~Securities~~same ~~Act~~day, ~~(17~~as Chief ~~CFR~~Financial Officer of Bio-Bridge Science, Inc. Mr. Lee will ~~230~~remain a consultant to the Company.~~425)~~

~~¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)~~SIGNATURE

~~¨ Pre-commencement~~Pursuant ~~communications pursuant~~ to ~~Rule~~the ~~14d-2(b)~~requirements ~~under~~of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this ~~(17~~report ~~CFR~~to ~~240~~be signed on its behalf by the undersigned hereunto duly authorized.~~14d-2(b))~~

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

	Bio-Bridge Science, Inc.

Date: November 12, 2010	By:	/s/ Dr. Liang Qiao
		Name: Dr. Liang Qiao

This Form 8-K and other reports filed by the Registrant from time to time with the Securities and Exchange Commission (collectively the “Filings”) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Registrant’s management as well as estimates and assumptions made by the Registrant’s management. When used in the Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant’s management identify forward looking statements. Such statements reflect the current view of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrant’s industry, operations and results of operations and any businesses that may be acquired by the Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Item 8.01 Other Events

On April 12, 2010, Bio-Bridge Science, Inc. ("Bio-Bridge Science") issued a press release announcing that the Company was granted a patent in Japan for the papilloma pseudovirus technology, exclusively licensed from Loyola University Chicago. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number		Description
99.1		Press Release issued by Bio-Bridge Science, Inc., dated April 12, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		BIO-BRIDGE SCIENCE, INC.
Date:	April 12, 2010
By:		/s/ Dr. Liang Qiao
Name		Dr. Liang Qiao
Title:		Chief Executive Officer

Filing Compare · BIO BRIDGE SCIENCE INC